Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Candidate Surrogate End Points for ESRD after AKI
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Departments of Epidemiology, Baltimore, Maryland, USA.
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Departments of Epidemiology, Baltimore, Maryland, USA.
Show others and affiliations
2016 (English)In: Journal of the American Society of Nephrology, ISSN 1046-6673, E-ISSN 1533-3450, Vol. 27, no 9, 2851-2859 p.Article in journal (Refereed) Published
Abstract [en]

AKI, a frequently transient condition, is not accepted by the US Food and Drug Association as an end point for drug registration trials. We assessed whether an intermediate-term change in eGFR after AKI has a sufficiently strong relationship with subsequent ESRD to serve as an alternative end point in trials of AKI prevention and/or treatment. Among 161,185 United States veterans undergoing major surgery between 2004 and 2011, we characterized in-hospital AKI by Kidney Disease Improving Global Outcomes creatinine criteria and decline in eGFR from prehospitalization to postdischarge time points and quantified associations of these values with ESRD and mortality over a median of 3.8 years. An eGFR decline of ≥30% at 30, 60, and 90 days after discharge occurred in 3.1%, 2.5%, and 2.6%, of survivors without AKI and 15.9%, 12.2%, and 11.7%, of survivors with AKI. For patients with in-hospital AKI compared with those with no AKI and stable eGFR, a 30% decline in eGFR at 30, 60, and 90 days after discharge demonstrated adjusted hazard ratios (95% confidence intervals) of ESRD of 5.60 (4.06 to 7.71), 6.42 (4.76 to 8.65), and 7.27 (5.14 to 10.27), with corresponding estimates for 40% decline in eGFR of 6.98 (5.21 to 9.35), 8.03 (6.11 to 10.56), and 10.95 (8.10 to 14.82). Risks for mortality were smaller but consistent in direction. A 30%-40% decline in eGFR after AKI could be a surrogate end point for ESRD in trials of AKI prevention and/or treatment, but additional trial evidence is needed.

Place, publisher, year, edition, pages
American Society of Nephrology , 2016. Vol. 27, no 9, 2851-2859 p.
Keyword [en]
acute renal failure, end stage kidney disease, glomerular filtration rate
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:liu:diva-129985DOI: 10.1681/ASN.2015070829ISI: 000382270500029PubMedID: 26857682OAI: oai:DiVA.org:liu-129985DiVA: diva2:945839
Note

Funding agencies: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [K08DK092287]; National Kidney Foundation; National Institutes of Health/NIDDK [R01DK100446, R01DK096920]; Department of VA, Veterans Health Administration, Office of Research and De

Available from: 2016-07-04 Created: 2016-07-04 Last updated: 2017-11-28Bibliographically approved

Open Access in DiVA

fulltext(1329 kB)